Didanosine

NOT RECOMMENDED AS AN ESSENTIAL MEDICINE

Section: 6. Anti-infective medicines > 6.4. Antiviral medicines > 6.4.2. Antiretrovirals > 6.4.2.1. Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

EMLc | ATC codes: J05AF02

Indication	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified ICD11 code: 1C62.Z
INN	Didanosine
Medicine type	Chemical agent
List type	Core
Formulations	**Oral > Liquid:** 100 mg buffered powder for oral solution ; 167 mg buffered powder for oral solution ; 250 mg buffered powder for oral solution **Oral > Solid:** 25 mg buffered chewable dispersible tablet ; 50 mg buffered chewable dispersible tablet ; 100 mg buffered chewable dispersible tablet ; 150 mg buffered chewable dispersible tablet ; 200 mg buffered chewable dispersible tablet ; 125 mg unbuffered enteric coated capsule ; 200 mg unbuffered enteric coated capsule ; 250 mg unbuffered enteric coated capsule ; 400 mg unbuffered enteric coated capsule
EML status history	First added in 2002 (TRS 914) Changed in 2007 (TRS 950) Removed in 2015 (TRS 994)
Sex	All
Age	Also recommended for children
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more about patents.
Wikipedia	Didanosine
DrugBank	Didanosine

Summary of evidence and Expert Committee recommendations

Didanosine was recommended for deletion from the EML and EMLc as it was not longer aligned with dosing guidelines in the 2013 WHO Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection (1). References: Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: World Health Organization; 2013. Available from: http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf.

